List of Figures
Figure 1: Number of Products under Development for Chronic Kidney Disease (Chronic Renal Failure)
Figure 2: Number of Products under Development by Companies, Chronic Kidney Disease (Chronic Renal Failure)
Figure 3: Number of Products under Development by Universities/Institutes, Chronic Kidney Disease (Chronic Renal Failure)
Figure 4: Number of Products under Development for Kidney Fibrosis
Figure 5: Number of Products under Development by Companies, Kidney Fibrosis
Figure 6: Number of Products under Development for Polycystic Kidney Disease, Kidney Fibrosis
Figure 7: Number of Products under Development by Companies, Kidney Fibrosis
Figure 8: Number of Products under Development for End-Stage Kidney Disease (End-Stage Renal Disease or ESRD)
Figure 9: Number of Products under Development by Companies, End-Stage Kidney Disease (End-Stage Renal Disease or ESRD)
Figure 10: Number of Products by Top 10 Targets, Chronic Kidney Disease (Chronic Renal Failure)
Figure 11: Number of Products by Stage and Top 10 Targets, Chronic Kidney Disease (Chronic Renal Failure)
Figure 12: Number of Products by Top 10 Mechanism of Actions, Chronic Kidney Disease (Chronic Renal Failure)
Figure 13: Number of Products by Stage and Top 10 Mechanism of Actions, Chronic Kidney Disease (Chronic Renal Failure)
Figure 14: Number of Products by Routes of Administration, Chronic Kidney Disease (Chronic Renal Failure)
Figure 15: Number of Products by Stage and Routes of Administration, Chronic Kidney Disease (Chronic Renal Failure)
Figure 16: Number of Products by Top 10 Molecule Types, Chronic Kidney Disease (Chronic Renal Failure)
Figure 17: Number of Products by Stage and Top 10 Molecule Types, Chronic Kidney Disease (Chronic Renal Failure)
Figure 18: Number of Products by Top 10 Targets, Kidney Fibrosis
Figure 19: Number of Products by Stage and Top 10 Targets, Kidney Fibrosis
Figure 20: Number of Products by Top 10 Mechanism of Actions, Kidney Fibrosis
Figure 21: Number of Products by Stage and Top 10 Mechanism of Actions, Kidney Fibrosis
Figure 22: Number of Products by Stage and Routes of Administration, Kidney Fibrosis
Figure 23: Number of Products by Top 10 Molecule Types, Kidney Fibrosis
Figure 24: Number of Products by Stage and Top 10 Molecule Types, Kidney Fibrosis
Figure 25: Number of Products by Top 10 Targets, Polycystic Kidney Disease
Figure 26: Number of Products by Stage and Top 10 Targets, Polycystic Kidney Disease
Figure 27: Number of Products by Top 10 Mechanism of Actions, Polycystic Kidney Disease
Figure 28: Number of Products by Stage and Top 10 Mechanism of Actions, Polycystic Kidney Disease
Figure 29: Number of Products by Routes of Administration, Polycystic Kidney Disease
Figure 30: Number of Products by Stage and Routes of Administration, Polycystic Kidney Disease
Figure 31: Number of Products by Molecule Types, Polycystic Kidney Disease
Figure 32: Number of Products by Stage and Molecule Types, Polycystic Kidney Disease
Figure 33: Number of Products by Targets, End-Stage Kidney Disease (End-Stage Renal Disease or ESRD)
Figure 34: Number of Products by Stage and Targets, End-Stage Kidney Disease (End-Stage Renal Disease or ESRD)
Figure 35: Number of Products by Mechanism of Actions, End-Stage Kidney Disease (End-Stage Renal Disease or ESRD)
Figure 36: Number of Products by Stage and Mechanism of Actions, End-Stage Kidney Disease (End-Stage Renal Disease or ESRD)
Figure 37: Number of Products by Molecule Types, End-Stage Kidney Disease (End-Stage Renal Disease or ESRD)
Figure 38: Number of Products by Stage and Molecule Types, End-Stage Kidney Disease (End-Stage Renal Disease or ESRD)